Opendata, web and dolomites

Vaprosep

Validation of Progranulin as Biomarker in Diagnostics and Prognosis of Sepsis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Vaprosep project word cloud

Explore the words cloud of the Vaprosep project. It provides you a very rough idea of what is the project "Vaprosep" about.

structured    excellent    subsequent    monitoring    data    host    validation    1000    literature    scientific    health    infection    interviewed    inflammatory    reaction    500    hospital    infectious    worldwide    sepsis    agent    opinion    therapy    differentiation    validated    property    solidity    strategy    care    reduce    mediagnost    infrastructure    market    patient    therapeutic    bodies    feasibility    successfully    clinical    unnecessary    reimbursement    guarantee    mean    prognosis    length    intellectual    inducing    complete    sensitive    employees    point    course    preliminary    antibiotic    administrative    prove    regulatory    strategic    biomarker    systemic    leaders    12    time    stay    hospitals    picture    direct    progranulin    completion    questionnaire    incidence    contact    rate    day    avoidance    routine    detection    notified    qualified    094    economic    technically    successful    multiplex    disease    regarding    delay    icu    advantages    million   

Project "Vaprosep" data sheet

The following table provides information about the project.

Coordinator
MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH 

Organization address
address: ASPENHAUSTRASSE 25
city: REUTLINGEN
postcode: 72770
website: www.mediagnost.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.mediagnost.de/en/news/summary-of-sme-instrument-phase-i-project-vaprosep-2/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIAGNOST GESELLSCHAFT FUR FORSCHUNG UND HERSTELLUNG VON DIAGNOSTIKA GMBH DE (REUTLINGEN) coordinator 50˙000.00

Map

 Project objective

Sepsis is a complex, systemic and inflammatory host reaction on an infection and with worldwide 1.5 million cases per year a health challenge. There is a strong need for a reliable biomarker like progranulin. Preliminary data prove that progranulin allows a highly sensitive and specific detection of sepsis, a monitoring of infection without time delay, prognosis regarding disease course and a differentiation between the infectious agent inducing sepsis.

Economic advantages of progranulin as biomarker are the reduction of the length of stay in the ICU (500-1000€ / day) and avoidance of unnecessary antibiotic therapy (10-500€ / day). Thus, the hospital can improve patient care and reduce therapeutic costs by a progranulin measurement for 5-10€. A mean incidence rate of 0.094% results in a 12 million euro market in the US and EU. Based on intellectual property this market is available only for Mediagnost. Successfully validated, progranulin measurement will be introduced in third level hospitals in the EU. The subsequent strategic product development includes point of care and multiplex test systems.

Mediagnost already has a technically validated test system for this biomarker available, therefore the overall objectives of this study are the clinical validation of progranulin measurement in sepsis and its implementation in clinical routine. Specifically, in phase I the economic potential of this biomarker is evaluated.

These objectives are addressed during phase I in a feasibility study including market and cost analysis. Key opinion leaders in the EU are interviewed by a structured questionnaire to evaluate scientific solidity and market potential. In direct contact to EU Notified Bodies the best regulatory strategy is evaluated. Further, literature research will complete the picture of the market and reimbursement requirements. Excellent infrastructure and highly qualified scientific and administrative employees guarantee the successful completion of this work.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VAPROSEP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VAPROSEP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More